<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="542">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514003</url>
  </required_header>
  <id_info>
    <org_study_id>COVITA</org_study_id>
    <nct_id>NCT04514003</nct_id>
  </id_info>
  <brief_title>The Corona and COVID-19 Study in Telemark and Agder</brief_title>
  <acronym>COVITA</acronym>
  <official_title>The Corona and COVID-19 Study in Telemark and Agder - COVITA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset Telemark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through SARS-CoV-2 IgG testing of PCR positive and negative cases the study will follow the
      COVID-19 immune response by monitoring the SARS-CoV-2 IgG antibody levels over a period of
      two years. Further, risk factors will be identified by the use of the test-negative design
      including population controls, allowing comparison of participants with positive and negative
      tests, and with population controls (triangulation). Special emphasis will be on high risk
      groups in general and on different occupational, environmental and socio-economic groups in
      particular. Finally, severity of illness, deaths and the use of health care during will be
      assessed using national register data from Telemark and Agder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

      The main objectives are:

        1. Monitor the incidence of COVID-19 and the development of the SARS-CoV-2-IgG levels of
           cases in Agder and Telemark over a period of two years (WP1).

        2. Identify risk factors for COVID-19 by comparison of SARS-CoV-2 antibody positive and
           negative cases in Telemark and Agder, and comparison of these groups separately with
           population controls (WP2).

        3. The incidence of neurocognitive symptoms and fatigue in COVID-19 patients (WP3).

        4. Investigation of severity, death and the use of health care for the COVID-19 patients
           based on data from national registers (WP4).

      The main exposures are (WP1-3):

        -  Infection (mild, severe) with COVID-19.

        -  Occupational risk factors assessed by occupational codes (ISCO88) and job exposure
           matrix categorisation.

        -  Environmental risk factors (road traffic outside bedroom window, travel by foot or
           bicycle alongside busy roads, and the use of a fireplaces in residential homes. Further,
           estimated measurements of air pollution may be linked to participants' home address.

        -  Socioeconomic status; age, sex, comorbidity, medication use, lifestyle factors (smoking,
           BMI, physical activity, others), geographic region/municipality, education and income.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 IgG antibody level</measure>
    <time_frame>2020-2023</time_frame>
    <description>Serum Levels of SARS-CoV-2 IgG antibody and the Development of these over a two years period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factors for COVID-19</measure>
    <time_frame>2020-2026</time_frame>
    <description>Different risk factors (age, sex, education, comorbidity, occupational and environmental exposure will be assessed</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SARS-CoV-2 PCR positive cases</arm_group_label>
    <description>Antibody tests will be performed every 6 months for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 PCR negative cases</arm_group_label>
    <description>Antibody tests will be performed every 6 months for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population controls</arm_group_label>
    <description>A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples for SARS-CoV-2 IgG antibody testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inhabitants of Agder and Telemark County in Norway fulfilling the inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 85 years

          -  Performed SARS-CoV-2 PCR test

        Exclusion Criteria:

          -  Non-Norwegian speakers.

          -  Deceased

          -  inability to answer questionnaire due to dementia or similar conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kristin M. Fell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sykehuset Telemark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Kristin M. Fell, PhD</last_name>
    <phone>+4735003118</phone>
    <email>annfel@sthf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Telemark Hospital</name>
      <address>
        <city>Skien</city>
        <state>Vestfold And Telemark</state>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sykehuset Telemark</investigator_affiliation>
    <investigator_full_name>Anne Kristin M. Fell</investigator_full_name>
    <investigator_title>Associate Professor, senior physician</investigator_title>
  </responsible_party>
  <keyword>Immunity</keyword>
  <keyword>Risk factors</keyword>
  <keyword>Test-negative design</keyword>
  <keyword>Population controls</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

